Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients

被引:0
|
作者
Schubert, J.
Young, N. S.
Luzzatto, L.
Brodsky, R. A.
Socie, G.
Rother, R. P.
Rollins, S. A.
Hillmen, P.
机构
[1] Saarland Univ, Sch Med, Homburg, Germany
[2] NHLBI, Bethesda, MD 20892 USA
[3] Ist Toscano Tumori, Florence, Italy
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Hosp St Louis, Paris, France
[6] INSERM, Paris, France
[7] Alexion Pharmaceut Inc, Cheshire, CT USA
[8] Leeds Gen Infirm, Leeds, W Yorkshire, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7087
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Lack of correlation of eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients with myeloproliferative disorders, myelodysplastic syndromes, acute leukemias or aplastic anemia with long-term treatment
    Schubert, J.
    Young, N. S.
    Luzzatto, L.
    Brodsky, R. A.
    Socie, G.
    Rother, R. P.
    Rollins, S. A.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Paroxysmal nocturnal hemoglobinuria (PNH) and hematologic malignancies, myelodysplastic disorders, or myeloproliferative syndromes.
    Harris, JW
    Medof, ME
    BLOOD, 1997, 90 (10) : 2706 - 2706
  • [3] Occurrence of acute leukemia and myelodysplastic disorders in paroxysmal nocturnal hemoglobinuria (PNH).
    Harris, JW
    Medof, ME
    BLOOD, 1997, 90 (10) : 2705 - 2705
  • [4] Results of Long-Term Therapy with a Biosimilar of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Kulagin, Alexander D.
    Ptushkin, Vadim V.
    Lukina, Elena A.
    Davydkin, Igor L.
    Korobkin, Alexander V.
    Konstantinova, Tatiana S.
    Komartseva, Elena Yu.
    Minaeva, Natalia V.
    Mitina, Tatiana A.
    Klimova, Olesya U.
    Arshanskaya, Evgeniya G.
    Latyshev, Vitalii D.
    Markova, Oksana A.
    Zuev, Eugene V.
    ACTA HAEMATOLOGICA, 2024,
  • [5] Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Brodsky, Robert A.
    de Castro, Carlos, III
    Schrezenmeier, Hubert
    Risitano, Antonio M.
    Schubert, Joerg
    Maciejewski, Jaroslaw P.
    Duehrsen, Ulrich
    Luzzatto, Lucio
    Muus, Petra
    Szer, Jeffrey
    Socie, Gerard
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 1720 - 1721
  • [6] Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab
    Vekemans, Marie-Christiane
    Lambert, Catherine
    Ferrant, Augustin
    Saussoy, Pascale
    Havelange, Violaine
    Debieve, Frederic
    Van den Neste, Eric
    Michaux, Lucienne
    BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (04) : 464 - 466
  • [7] Cytogenetics of uncomplicated paroxysmal nocturnal hemoglobinuria (PNH) and PNH in association with hematologic malignancy, myelodysplastic disorders, or myeloproliferative syndrome.
    Harris, JW
    Medof, ME
    BLOOD, 1997, 90 (10) : 2704 - 2704
  • [8] Long-Term Survival Benefit of Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria: Data from the International PNH Registry
    Terriou, Louis
    Patriquin, Christopher J.
    Griffin, Morag
    Lee, Jong Wook
    Gustovic, Philippe
    Patel, Ami S.
    Szer, Jeff
    BLOOD, 2021, 138
  • [9] Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Szer, Jeffrey
    Muus, Petra
    Roeth, Alexander
    Elebute, M. O.
    Risitano, Antonio M.
    Schrezenmeier, Hubert
    Maciejewski, Jaroslaw P.
    Urbano-Ispizua, Alvaro
    de Castro, Carlos Manuel, III
    Socie, Gerard
    Brodsky, Robert A.
    BLOOD, 2012, 120 (21)
  • [10] Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Mojcik, C. F.
    Young, N. S.
    Luzzatto, L.
    Socie, G.
    Hillmen, P.
    Brodsky, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)